Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

Global Macrophage Migration Inhibitory Factor Pipeline Report 2016 - Research and Markets

Research and Markets
Posted on: 17 Oct 16

Research and Markets has announced the addition of the "Macrophage Migration Inhibitory Factor (Glycosylation Inhibiting Factor or L Dopachrome Isomerase or L Dopachrome Tautomerase or Phenylpyruvate Tautomerase or MIF or EC 5.3.2.1 or EC 5.3.3.12) - Pipeline Review, H2 2016" report to their offering.

Macrophage Migration Inhibitory Factor pipeline Target constitutes close to 13 molecules. Out of which approximately 12 molecules are developed by Companies and remaining by the Universities/Institutes. The molecules developed by Companies in Phase II, Preclinical and Discovery stages are 2, 8 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Macrophage Migration Inhibitory Factor - Pipeline Review, H2 2016, outlays comprehensive information on the Macrophage Migration Inhibitory Factor targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Macrophage Migration Inhibitory Factor targeted therapeutics development, features dormant and discontinued projects and latest news and press releases.

Key Topics Covered:

  1. Introduction
  2. Macrophage Migration Inhibitory Factor Overview
  3. Therapeutics Development
  4. Pipeline Products for Macrophage Migration Inhibitory Factor - Overview
  5. Pipeline Products for Macrophage Migration Inhibitory Factor - Comparative Analysis
  6. Macrophage Migration Inhibitory Factor - Therapeutics under Development by Companies
  7. Macrophage Migration Inhibitory Factor - Therapeutics under Investigation by Universities/Institutes
  8. Macrophage Migration Inhibitory Factor Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. Macrophage Migration Inhibitory Factor - Products under Development by Companies
  13. Macrophage Migration Inhibitory Factor - Products under Investigation by Universities/Institutes
  14. Macrophage Migration Inhibitory Factor - Companies Involved in Therapeutics Development
  • Kyorin Pharmaceutical Co., Ltd.
  • PDS Biotechnology Corporation
  • Shire Plc

For more information about this report visit http://www.researchandmarkets.com/research/n4hnvd/macrophage

View source version on businesswire.com: http://www.businesswire.com/news/home/20161017005779/en/

Business Wire
www.businesswire.com

Last updated on: 17/10/2016

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.